The following content is sponsored by Americans for a limited government:
America's first drug pricing has begun.
President Trump has pledged to lower US drug prices. President Trump understands that, contrary to the typical politicians who want to score points with false promises but prefer not to achieve anything, mediators, government bureaucracy and European price controls mean that Americans pay more than other developed countries with prescription drugs. And unlike past presidents, he's doing something about it.
Pharmacy Benefit Managers (PBMS) intermediaries have increased drug prices by about 50%. PBMS and major insurance companies cost 25%. In addition to the large hospitals, they abused a lesser-known government program called the 340B, earning another $66 billion or 10%. Government intermediaries take the remainder through statutory rebates and fees.
“We knock out the intermediaries. Trump said in December. “Frankly, they're scary intermediaries who make more money than drug companies, and they're not doing anything except they're intermediaries.”
PBMs negotiate drug prices and rebates with manufacturers, but instead of handing over their savings to patients, they put most of them in their pocket. This look-like practice is one of the reasons why Trump and the Federal Trade Commission are there Cracks With the largest PBM.
President Trump will either eliminate PBM completely or significantly reduce the impact on drug pricing. During his first term, Trump's rebate rules would have forced PBMs to provide billions and billions of savings to seniors. Biden has abandoned Trump's rebate rules in the so-called inflation reduction law. It cost billions of dollars and won more PBMS. Reviving rebate rules will bring billions of dollars back to seniors and lower drug prices.
This week, Trump signed an executive order to make medical prices transparent. “When medical prices are hidden, big companies like hospitals and insurance companies are profiting at the expense of American patients. Price transparency helps patients and employers cut their health prices and help them get the best deals in healthcare,” the White House said. Trump will further reduce even lower drug prices by exposing the 340B abuse through this executive order and showing the real price to intermediaries.
Trump will bring lower drug prices by making Europe pay a fair share. Trump ends global freeriding and fixes over the years Drug pricing imbalance European countries have failed to pay a fair share for treatments developed in the United States.
For decades, Americans have been burdened with the high cost of drug development, but Europe and other wealthy countries have imposed price control on American exports that force pharmaceutical companies to fall below market value. This will turn the burden of research and development costs into American consumers. It also causes shortages, depriving European patients of life-saving treatments. Europe was once a leader in medical innovation. Price control killed it. Currently, America is a leader in medical innovation. However, adopting European price management will end leadership and China will take over. China has already taken steps to ensure that it happens and is betting on our lead's failure.
Trump will renegotiate international trade agreements and pressure foreign governments to pay fair market prices. Just as he forced his NATO allies “Pay their fair share.”Trump is responsible for European countries for paying fair prices for drugs rather than relying on American taxpayers.
America's first drug policy brings much needed transparency and competition to the drug market. By reforming the PBM and 340B, reducing the influence of intermediaries and ending at the world's freedom, the Trump administration will provide lower prescription drug prices than Americans need. That's America's First Drug pricing.
